Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 5/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
| ▸ | RAF1 | P04049 | 1/20 | 0.34 |
| ▸ | BRAF | P15056 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19808858 | 0.86 | LMNA (0.41) | MAPTEGLN1MAPK1TDP1KDM4E | |
| SCHEMBL19808816 | 0.84 | L3MBTL1 (0.48) | MAPTEGLN1L3MBTL1F10CYP3A4 | |
| SCHEMBL19808921 | 0.84 | TDP1 (0.46) | MAPTL3MBTL1GAATDP1PPARG | |
| SCHEMBL19808841 | 0.82 | MAPT (0.53) | MAPTEGLN1L3MBTL1F10CYP3A4 | |
| SCHEMBL19808823 | 0.82 | JAK2 (0.48) | MAPTEGLN1L3MBTL1F10 | |
| SCHEMBL19808805 | 0.80 | MAPT (0.51) | MAPTEGLN1L3MBTL1F10CYP3A4 | |
| SCHEMBL19808905 | 0.79 | CYP1A2 (0.42) | MAPTEGLN1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL19808833 | 0.79 | LMNA (0.51) | MAPTEGLN1GAAKDM4EKDR | |
| SCHEMBL19808917 | 0.78 | L3MBTL1 (0.40) | MAPTEGLN1L3MBTL1GAAMAPK1 | |
| SCHEMBL19808864 | 0.77 | P2RX3 (0.43) | MAPTEGLN1L3MBTL1CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3275881-B1 | COMPOUND OF 5-HYDROXYL-1,7-NAPHTHYRIDINE SUBSTITUTED BY ARYLOXY OR HETEROOXY, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF | SHENYANG SUNSHINE PHARMACEUTICAL CO LTD (CN) | 2021-08-04 | — | — | EP | disclosed |
| US-10100051-B2 | Compound of 5-hydroxyl-1,7-naphthyridine substituted by aryloxy or heteroaryloxy, preparation method thereof and pharmaceutical use thereof | SHENYANG SUNSHINE PHARMACEUTICAL CO. LTD. (CN) | 2018-10-16 | — | — | US | disclosed |
| US-20180118739-A1 | COMPOUND OF 5-HYDROXYL-1,7-NAPHTHYRIDINE SUBSTITUTED BY ARYLOXY OR HETEROARYLOXY, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF | SHENYANG SUNSHINE PHARMACEUTICAL CO., LTD. (CN) | 2018-05-03 | — | — | US | disclosed |
| EP-3275881-A1 | COMPOUND OF 5-HYDROXYL-1,7-NAPHTHYRIDINE SUBSTITUTED BY ARYLOXY OR HETEROOXY, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF | Shenyang Sunshine Pharmaceutical Co., Ltd. (CN) | 2018-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118739-A1 | COMPOUND OF 5-HYDROXYL-1,7-NAPHTHYRIDINE SUBSTITUTED BY ARYLOXY OR HETEROARYLOXY, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF | HIF1AN, EGLN3, EGLN2 | MAPT 4849/4885EGLN1 7/4885L3MBTL1 4819/4885 |
| US-10100051-B2 | Compound of 5-hydroxyl-1,7-naphthyridine substituted by aryloxy or heteroaryloxy, preparation method thereof and pharmaceutical use thereof | HIF1AN, EGLN3, EGLN2 | MAPT 4849/4885EGLN1 7/4885L3MBTL1 4819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.